Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H41BrNO4 |
| Molecular Weight | 511.512 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 4 |
| E/Z Centers | 0 |
| Charge | 1 |
SHOW SMILES / InChI
SMILES
COC1=C(OC)C=C(C[N+]4(CCOCC[C@@H]2CC[C@H]3C[C@@H]2C3(C)C)CCOCC4)C(Br)=C1
InChI
InChIKey=DDHUTBKXLWCZCO-BVSLBCMMSA-N
InChI=1S/C26H41BrNO4/c1-26(2)21-6-5-19(22(26)16-21)7-11-31-12-8-28(9-13-32-14-10-28)18-20-15-24(29-3)25(30-4)17-23(20)27/h15,17,19,21-22H,5-14,16,18H2,1-4H3/q+1/t19-,21-,22-/m0/s1
Pinaverium, known under the brand name DICETEL, is a spasmolytic agent used for functional gastrointestinal disorders. It is a quaternary ammonium compound that acts as an atypical calcium antagonist to restore normal bowel function. It is shown to relieve GI spasm and pain, transit disturbances and other symptoms related to motility disorders and may be considered as effective first-lline therapy for patients with irritable bowel syndrome (IBS). Pinaverium is also used to help relieve symptoms caused by certain disorders of the gallbladder associated with secretion of bile. Pinaverium bromide is the common ingredient in formulations, mostly as oral tablets. Although it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada. DICETEL® (pinaverium bromide) is a calcium antagonist which inhibits the calcium influx by
blocking the voltage-dependent calcium channel at the smooth muscle cell level. It possesses a high degree of selectivity for the intestinal smooth muscle.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 1.75 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Dicetel Approved UseDICETEL® (pinaverium bromide) is indicated:
- for the treatment and relief of symptoms associated with irritable bowel syndrome (IBS):
abdominal pain, bowel disturbances and intestinal discomfort.
- for the treatment of symptoms related to functional disorders of the biliary tract. |
|||
| Palliative | Dicetel Approved UseDICETEL® (pinaverium bromide) is indicated:
- for the treatment and relief of symptoms associated with irritable bowel syndrome (IBS):
abdominal pain, bowel disturbances and intestinal discomfort.
- for the treatment of symptoms related to functional disorders of the biliary tract. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1714.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21308709/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PINAVERIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1730.7 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21308709/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PINAVERIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21308709/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PINAVERIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of probiotic Lactobacillus (Lacidofil® cap) for the prevention of antibiotic-associated diarrhea: a prospective, randomized, double-blind, multicenter study. | 2010-12 |
|
| [Tiaohe Ganpi Hexin Decoction in treatment of irritable bowel syndrome with diarrhea: a randomized controlled trial]. | 2009-09 |
|
| Irritable bowel syndrome: a mild disorder; purely symptomatic treatment. | 2009-04 |
|
| Effect of four medications associated with gastrointestinal motility on Oddi sphincter in the rabbit. | 2009 |
|
| Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. | 2008-11-13 |
|
| [Pinaverium bromide-induced esophageal ulcerations]. | 2008-06-18 |
|
| [Drug treatment of irritable bowel syndrome: an unmet need]. | 2007-03 |
|
| Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. | 2004 |
|
| [New approaches to diagnosing and treating hyperkinetic biliary dyskinesia associated with chronic acalculous cholecystitis]. | 2004 |
|
| [Randomized controlled clinical study on effect of Chinese compound changjitai in treating diarrheic irritable bowel syndrome]. | 2003-11 |
|
| Effect of pinaverium bromide on stress-induced colonic smooth muscle contractility disorder in rats. | 2003-03 |
|
| [Effects of dicetel on gastrointestinal motility and vegetative dysfunction in patients with duodenal ulcer]. | 2003 |
|
| [Current approaches to the diagnosis and treatment of irritable bowel syndrome]. | 2002-03-08 |
|
| Contraction of human colonic circular smooth muscle cells is inhibited by the calcium channel blocker pinaverium bromide. | 2001-06 |
|
| Increased calcium influx is responsible for the sustained mechanical tone in colon from dystrophic (mdx) mice. | 2001-05 |
Patents
Sample Use Guides
The usual adult dosage is 50 mg three times a day (total daily dose of 150 mg). The dosage may be increased up to a maximum of 100 mg taken three times a day (maximum total daily dose of 300 mg).
It is recommended that the tablet be taken with a glass of water during meals or snacks. The tablet should not be swallowed when in the lying position or just before bedtime.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
A03AX04
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
||
|
WHO-VATC |
QA03AX04
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
33724
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB03826MIG
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
PRIMARY | |||
|
DTXSID90860655
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
PRIMARY | |||
|
40479674
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
PRIMARY | |||
|
DB09090
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
PRIMARY | |||
|
PINAVERIUM
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
PRIMARY | |||
|
59995-65-2
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
PRIMARY | |||
|
100000085286
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
PRIMARY | |||
|
1970218-69-9
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
ALTERNATIVE | |||
|
2174
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
PRIMARY | |||
|
C013199
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
PRIMARY | |||
|
U2368VVE7O
Created by
admin on Mon Mar 31 21:02:24 GMT 2025 , Edited by admin on Mon Mar 31 21:02:24 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
